NOI to Sole Source to QuVa Pharma, Inc.

The National Institutes of Health (NIH) intends to award a one-year contract to QuVa Pharma, Inc. for the purchase of 503b compounded Intravenous (IV) Narcotics for patient care. The contract will be a firm fixed price sole source award basis. The proposed vendor, QuVa Pharma Inc., is the Original Manufacturer and has not designated other distributors of IV narcotics in the U.S. The acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures. • The contract is for a base year with an initial value of $110,000 and 4 optional years for a total of $684,000. • The medications will be used by the Clinical Center for patient care. • The contract is exempt from the requirements of FAR Part 6-Competition Requirements. • The determination by the Government not to compete the proposed requirement is solely within the discretion of the Government.